Men volunteering to take part in clinical trials are vital for improving treatments, including improving our understanding of the effects of hormone therapy.
BLOG: Abiraterone should continue to be available on the NHS and opened up to all men with newly diagnosed advanced prostated cancer, argues our policy manager Tim Windle, as the UK’s drug guidelines body is set to rule on the future of the treatment.
After we investigated complaints from men unable to get hold of the off-patent prostate cancer drug, bicalutamide, the British Generic Manufacturers' Association has told us problems with supply shouldn't last long.
Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.
BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.
A new type of treatment that alternately floods and starves the body of testosterone has shown good early results in men with advanced prostate cancer, according to new findings revealed today.
Following reports in the press yesterday of a US study into androgen deprivation therapy – a commonly used treatment for men with prostate cancer in the UK – Prostate Cancer UK's Dr Iain Le Guilliou investigates whether there's any solid proof behind claims it could double the risk of dementia.
Prostate Cancer UK and the Movember Foundation reveals new opportunities for diagnosing and treating aggressive prostate cancer
Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.